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Background: In resource-limited countries, estimating CD4-speciﬁc
incidence rates of mortality and morbidity among patients receiving
antiretroviral therapy (ART) may help assess the effectiveness of
care and treatment programmes, identify program weaknesses, and
inform decisions.
Methods: We pooled data from 13 research cohorts in 5 sub-
Saharan African (Benin, Burkina Faso, Cameroon, Cote d’Ivoire,
and Senegal) and 2 Asian (Cambodia and Laos) countries. HIV-
infected adults (18 years and older) who received ART in 1998–
2008 and had at least one CD4 count available were eligible.
Changes in CD4 counts over time were estimated by a linear mixed
regression. CD4-speciﬁc incidence rates were estimated as the
number of ﬁrst events occurring in a given CD4 stratum divided
by the time spent within the stratum.
Results: Overall 3917 adults (62% women) on ART were followed
up during 10,154 person-years. In the #50, 51–100, 101–200, 201–
350, 351–500, 501–650, and.650 cells/mm3 CD4 cells strata, death
rates were 20.6, 11.8, 6.7, 3.3, 1.8, 0.9, and 0.3 per 100 person-years;
AIDS rates were 50.5, 32.9, 11.5, 4.8, 2.8, 2.2, and 2.2 per 100
person-years; and loss-to-follow-up rates were 4.9, 6.1, 3.5, 3.1,
2.9, 1.7, and 1.2 per 100 person-years, respectively. Mortality and
morbidity were higher during the ﬁrst year after ART initiation.
Conclusions: In these resource-limited settings, death and AIDS
rates remained substantial after ART initiation, even in individuals
with high CD4 cell counts. Ensuring earlier ART initiation and
optimizing case ﬁnding and treatment for AIDS-deﬁning diseases
should be seen as priorities.
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INTRODUCTION
In the last decade, considerable efforts have been made to
scale-up antiretroviral therapy (ART) in resource-limited
countries, to decrease HIV/AIDS-related mortality and mor-
bidity.1–4 The number of patients on ART dramatically
increased from 400,000 in 2003, when the World Health Orga-
nization (WHO) launched the “3 by 5” initiative, to 6.6 million
in 2010. However, this latter ﬁgure only represents 47% of the
patients in need of treatment, while universal access to ART
was targeted for 2010.5,6 Moreover, mortality and morbidity
among treated patients was reported to be higher in resource-
limited settings than in rich countries, partly because patients
still frequently start ART at an advanced stage of HIV disease
with pronounced immunodeﬁciency.7–9
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The CD4 cell count is the most important determinant
of HIV-related mortality and morbidity.10–15 Incidence rates
of death or AIDS by CD4 cell count among patients receiving
ART in the context of resource-limited countries have been
mainly estimated in low CD4 cell count strata and based on
pre-ART CD4 values.12,16 Estimating these incidence rates
according to the current CD4 cell count (CD4-speciﬁc rates)
across a wide range of CD4 values could help inform clinical
outcomes in patients on ART and adapt treatment recommen-
dations to improve the quality of care and the effectiveness of
treatment programmes.
The reasons why CD4-speciﬁc rate estimates have
rarely been reported in sub-Saharan Africa are inherent to
the methodological limitations of cohort studies and of large
program databases.
In cohort studies, CD4 counts are measured regularly,
the magnitude of missing data and of loss to follow-ups are
limited, and morbidity/mortality are properly documented,
but the number of patients per CD4 stratum is limited. In
operational programmes, sample sizes are much larger, but
the rates of loss to follow-up and of missing data are high and
morbidity and mortality documentation is poorer.17
In this study, we pooled available data from cohorts of
HIV-infected adults on ART in low-resource settings, to
estimate CD4-speciﬁc rates of death and AIDS.
METHODS
Study Population
The ANRS 12222 collaboration was established in 2009
with the objective to describe CD4-speciﬁc rates of mortality
and morbidity among HIV-infected patients living in resource-
limited countries. In this collaboration, we pooled data from
research cohort studies sponsored by the French National
Agency for Research on AIDS and Viral Hepatitis (ANRS) or
associated partners in Africa and Asia from 1996 to 2009.
Methods and results among patients without ART have been
published elsewhere.17,18 For the present analysis, cohorts were
eligible if the initial study procedures included (1) repeated CD4
cell count measurements, (2) a follow-up period on ART, and
(3) an active strategy to retain patients. Within eligible cohorts,
patients were included if (1) they were aged 18 years or older at
enrolment, (2) they had at least one CD4 measurement available,
and (3) they were followed-up at least one day on ART.
Procedures
In all but one participating cohorts, visits, drugs, hospital-
izations, and biological or radiological tests were free of charge
for patients during the entire study period; in the Senegalese
cohort, ART was provided commensurate with their income for
most patients or free of charge for the others between 1998 and
2003 and became free for all patients thereafter.19 All studies
implemented the following procedures: scheduled visits once
a month up to every 3 months (except one cohort with visits
every 4 months during a ﬁrst calendar period and every 6
months thereafter); CD4 cell count measurements at the time
of ART initiation and every 6 months thereafter; active strate-
gies to contact patients who did not show up for a scheduled
visit (including phone calls, home visits, and hospital records);
standardized deﬁnitions and procedures to document ART ini-
tiation and follow-up events, and standardized data collection.
The absolute CD4 cell counts were determined using ﬂow
cytometers. All study protocols had been approved by the
national ethics committees or institutional review boards.
Statistical Analysis
The time scale considered in this analysis was the time
since ART initiation. Data were censored at the date of the
ﬁrst event among the following: death, AIDS-deﬁning event
(for morbidity analysis), last contact with the study team for
the patients lost to follow-up, or database cutoff date for this
study.
We considered the following CD4 cell count strata:
#50, 51–100, 101–200, 201–350, 351–500, 501–650, and
.650 cells/mm3. We ﬁrst determined the time spent in a given
CD4 cell count stratum by estimating the CD4 cell count evo-
lution at individual levels with a linear mixed effect model.
Patients were included in this model if they had at least one
CD4 measurement available in the last 6 months before ART
initiation. The ﬁxed effects were the participating cohort, gender,
baseline age, baseline CD4 cell count (#50, 51–150, 151–250,
and .250 cells/mm3), baseline WHO clinical stage, and year of
ART initiation (2004 or earlier versus after 2004). We used
a model with 2 slopes (a ﬁrst during the ﬁrst 3 months of fol-
low-up and a second thereafter) and a quadratic term on the
second slope. The random effects were composed of the 2 slopes
and of the quadratic term on the second slope. The underlying
assumptions were veriﬁed by graphically studying model resid-
uals. This model was performed using the MIXED procedure of
the SAS software, version 9.1 (SAS institute Inc., Cary, NC).
We then estimated the current CD4 cell count-speciﬁc
rates of death, of AIDS, of a combined criterion of death or
AIDS, and of loss to follow-up per 100 person-years by
dividing the number of ﬁrst given events that occurred in each
CD4 cell count stratum by the time spent in the corresponding
stratum (for patients who did not have the event) or by the
time between entry in the stratum and ﬁrst event (for patients
who experienced the event). Prevalent events at ART
initiation were excluded. AIDS events were deﬁned according
to the Centers for Disease Control and Prevention classiﬁca-
tion (CDC stage C). Patients were considered as lost to
follow-up if their last contact was more than 6 months before
the database cutoff for this study and if they were not known
to be dead. Conﬁdence intervals (95% CI) were calculated
assuming a Poisson distribution if the number of events was
less than 50 and normal approximation otherwise.
RESULTS
Characteristics of Patients
Among the 17 longitudinal cohort studies of HIV-infected
adults in resource-limited settings included in the ANRS 12222
collaboration, 13 followed patients on ART. These studies were
conducted in 5 sub-Saharan African countries (Benin, Burkina
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Faso, Cameroon, Cote d’Ivoire, and Senegal) and 2 Asian coun-
tries (Cambodia and Laos). Between August 1998 and June
2008, 4313 adults were followed at least one day with ART,
of whom 3917 (91%) had at least one CD4 cell count measure-
ment and were therefore included in the present analysis (2318
in Africa and 1599 in Asia). The main baseline characteristics of
patients are shown in Table 1. Two-thirds of patients were
women. The median age was 34 years and median pre-ART
CD4 cell count was 148 cells/mm3. The overall follow-up
cumulated was 10,154 person-years, of which one-third was
in the 201–350 CD4 cells/mm3 stratum and almost half was
in the CD4 strata above 350 cells/mm3. The median follow-
up was 2.3 years and median number of CD4 cell counts per
patient was 6.
Evolution of the CD4 Cell Count After
ART Initiation
Figure 1 shows the modelized CD4 cell count evolution
after ART initiation according to pre-ART value. The CD4
cell count increase was important in all CD4 strata during the
ﬁrst 3 months of treatment (more importantly in the highest
strata) and slowed down and differed according to strata
thereafter (P , 0.001). Beyond the ﬁrst months of treatment,
the lower the pre-ART CD4 cell count was, the higher the
CD4 increase was. At two years, the mean CD4 cell count
increase was 245 cells/mm3 for pre-ART CD4 cell count less than 50 cells/mm3 and 198 cells/mm3 for pre-ART CD4 cell
count more than 200 cells/mm3. At 4 years, the mean CD4
cell count increase was 281 and 204 cells/mm3, respectively.
We observed a curve level off after 2–3 years of ART in all
CD4 cell count strata.
Mortality and Morbidity
During follow-up, 335 patients (9%) died, 525 (13%)
experienced at least one AIDS-deﬁning event, and 760 (19%)
died or experienced at least one AIDS-deﬁning event. The
most frequent AIDS-deﬁning events were pulmonary tuber-
culosis (n = 249), disseminated tuberculosis (n = 121), recur-
rent bacterial pneumonia (n = 69), cryptococcosis (n = 50),
Cytomegalovirus infection (n = 42), toxoplasmosis (n = 35),
oesophageal candidiasis (n = 24), Kaposi’s sarcoma (n = 17),
wasting syndrome (n = 13), nontuberculous mycobacteriosis
(n = 11), and systemic mycosis (n = 11).
Mortality and morbidity rates decreased with increasing
current CD4 cell count (Figs. 2A, B). Death rates were 20.6
per 100 person-years in the #50 CD4 cells/mm3 stratum,
3.3 per 100 person-years in the 201–350 CD4 cells/mm3 stra-
tum, and 0.3 per 100 person-years in the .650 CD4 cells/mm3
stratum. AIDS rates were 50.5 per 100 person-years in the#50
CD4 cells/mm3 stratum, 4.8 per 100 person-years in the 201–
350 CD4 cells/mm3 stratum, and 2.2 per 100 person-years in
the.650 CD4 cells/mm3 stratum. Finally, the rates of death or
AIDS were 67.0 per 100 person-years in the #50 CD4/mm3
stratum, 7.5 in the 201–350 CD4 cells/mm3 stratum, and 2.5
per 100 person-years in the .650 CD4 cells/mm3 stratum.
Unsurprisingly, mortality and morbidity incidence rates were
TABLE 1. Baseline and Follow-up Characteristics of HIV-
Infected Patients With ART in Africa and Asia, ANRS 12222
Morbidity/mortality Collaboration
No. Participants 3917
Baseline characteristics
Women, % 62
Median age, yrs (IQR) 34 (29–40)
Median CD4 count/mm3 (IQR) 148 (54–224)
WHO stage 3 or 4, % 48
Follow-up characteristics with ART
Follow-up (yrs), median (IQR) 2.3 (1.5–3.5)
Number of CD4 count per patient, median (IQR) 6 (4–10)
Person-years of follow-up
Overall 10,154
Per CD4 stratum/mm3*
0–50 102
51–100 280
101–200 1505
201–350 3564
351–500 2807
501–650 1227
.650 669
Status at study termination, %
Alive 84
Lost to follow-up 8
Dead 9
*Modelized.
IQR, interquartile range.
FIGURE 1. Mean increase in CD4 cell count (CD4 modelized
adjusted on covariates [cohort, gender, baseline age, baseline
CD4 cell count, baseline WHO clinical stage, and year of ART
initiation]) among HIV-infected patients receiving ART in Africa
and Asia by baseline value, ANRS 12222 Morbidity/Mortality
Collaboration. *Mean CD4 increase at 3 months; †Mean CD4
increase at 2 years; and ‡Mean CD4 increase at 4 years.
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higher during the ﬁrst year after ART initiation compared with
subsequent years (Figs. 3A, B).
Loss to Follow-up
Two hundred ninety-four patients (8%) were lost to
follow-up. The incidence rate of loss to follow-up tended to
decrease when the current CD4 cell count increased (Fig. 4).
In the #50, 201–350, and .650 CD4 cells/mm3 strata, loss-
to-follow-up incidence rates were 4.9, 3.1, and 1.2 per 100
person-years, respectively. There was no signiﬁcant differ-
ence between the ﬁrst year and subsequent years.
DISCUSSION
This pooled analysis of data from 13 cohorts in Africa
and Asia allowed us to estimate the incidence rates of death,
AIDS, a combined criterion of death or AIDS, and loss to
follow-up by current CD4 cell count among HIV-infected adults
receiving ART in resource-limited countries. As expected,
mortality and morbidity incidence rates decreased with increas-
ing CD4 count and were higher in the ﬁrst year of treatment.
However, mortality and morbidity rates remained substantial,
even in high CD4 cell count strata. Finally, the rate of loss to
follow-up tended to decrease with increasing CD4 cell count,
without signiﬁcant difference between the ﬁrst year and
thereafter.
In a previous report of mortality and morbidity CD4-
speciﬁc rates among untreated patients in the same settings, we
found higher mortality rates in the CD4 cell count strata below
200 cells/mm3, similar mortality rates above 200 cells/mm3,
and similar AIDS rates across the spectrum of CD4 counts.17,18
FIGURE 2. A, Mortality and morbidity incidence rates among
HIV-infected patients receiving ART in Africa and Asia by cur-
rent CD4 cell count, ANRS 12222 Morbidity/Mortality Col-
laboration. B, Mortality and morbidity incidence rates among
HIV-infected patients receiving ART in Africa and Asia by cur-
rent CD4 cell count (focus on CD4 .200 cells/mm3), ANRS
12222 Morbidity/Mortality Collaboration.
FIGURE 3. A, Mortality incidence rates during the first year
and thereafter among HIV-infected patients receiving ART in
Africa and Asia by current CD4 cell count, ANRS 12222 Mor-
bidity/Mortality Collaboration. B, AIDS incidence rates during
the first year and thereafter among HIV-infected patients
receiving ART in Africa and Asia by current CD4 cell count,
ANRS 12222 Morbidity/Mortality Collaboration.
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Overall, our estimates of mortality seemed to be in the range of
those reported among patients receiving ART in Western
countries, while our estimates of AIDS rates tended to be
higher. Reported death rates among patients with a CD4 cell
count between 351 and 500 cells/mm3 were 1.6 per 100 per-
son-years in the North American AIDS Cohort Collaboration on
Research and Design (NA-ACCORD),20 and 0.8 per 100 person-
years in the Concerted Action on SeroConversion to AIDS and
Death in Europe (CASCADE).21 In patients with .500 CD4
cells/mm3, death rates were 1.3 per 100 person-years in the
NA-ACCORD,20 0.4 per 100 person-years in the Collaboration
of Observational HIV Epidemiological Research in Europe
(COHERE)22 and 0.7 per 100 person-years in CASCADE.21
Finally, the death rate was 0.7 per 100 person-years among
patients with a CD4 cell count.350 cells/mm3 in the EuroSIDA
study.23 This latter study also reported death rates similar to our
estimates in lower CD4 cell count strata and lower rates of AIDS
across the entire CD4 spectrum.23
Of note, three-quarters of patients included in studies
from high-income countries were male, whereas two-thirds of
our patients were women, and mortality has been repeatedly
reported to be higher in men.11,21
In sub-Saharan Africa, a recent study in Kenya,
Malawi, and Uganda reported estimates of mortality after
the ﬁrst 9 months of ART, but a comparison with our study is
difﬁcult because of methodological differences.24 In South Africa,
reported death rates in patients on ART were 2.0 per 100 person-
years among patients with 300–499 CD4 cells/mm3, and 1.2 per
100 person-years among those with CD4 .500 cells/mm3.25
Three main recommendations can be drawn, directly or
indirectly, from our ﬁndings to improve the quality of HIV
care and maximize the effectiveness of ART programmes in
resource-limited countries.
First, despite the present global economic crisis and its
negative consequences on HIV/AIDS funding, it is critical to
ensure that national AIDS programmes, who have devoted
considerable efforts to adopt the WHO 2010 recommendation
of increasing the ART initiation CD4 threshold from 200 cells/
mm3 to 350 cells/mm3 in asymptomatic patients, do not reverse
their guidelines, as some are tempted to do.5,26,27 Rather, addi-
tional resources both at international and national levels should
be mobilized. Moreover, the national programmes that have
not yet adopted the CD4 threshold of 350 cells/mm3 should
move toward it. Finally, initiation of ART above the CD4
threshold of 350 cells/mm3 in asymptomatic or mildly symp-
tomatic patients in low-resource settings should be envisaged
in the near future. As a matter of fact, rich countries with lower
rates of AIDS in patients with .350/mm3 already recommend
starting ART .500 cells/mm3 or at any CD4 count.28,29
Second, additional efforts in terms of laboratory equip-
ment, training, mentoring, and supervision of health-care
workers, accessibility to preventive and curative drugs, and
education of patients are necessary to improve the diagnosis and
treatment of opportunistic infections in patients receiving ART.
Third, the schedule of clinical visits should take into
account not only the time on ART but also the current CD4
cell count. This ﬁnding underlines once more the need for
immunological monitoring in treated patients.30–32
The main limitation to our study was the relatively
small sample size, especially in the CD4 cell count strata
,100 cells/mm3. However, estimates of incidence rates in
higher CD4 cell count strata, where the sample size was
larger, are of higher interest as they concern the current debate
on the timing of ART initiation.20,33–35 The sample size also
prevented any data stratiﬁcation on major determinants of
mortality and morbidity such as gender and age and on dura-
tion of ART beyond the ﬁrst year. Data in larger and longer-
term cohort studies would be useful. On the other hand, our
mortality and morbidity estimates should be seen as minimum
rates, due to unknown events (deaths or AIDS) among
patients lost to follow-up.36 Indeed, although censoring due
to losses to follow-up may be informative, they were treated
as censoring due to end of the study period. The number and
distribution of events across CD4 cell count strata among the
patients lost to follow-up are unknown but our mortality and
morbidity estimates were probably more accurate in the high
CD4 cell count strata focused in the present study than in the
low strata because the rate of losses to follow-up on the one
hand and the expected rate of events (deaths or AIDS) in
those patients lost to follow-up on the other hand were lower
in the former. It is worth noting that the rates of loss to
follow-up in high CD4 cell count strata were comparable with
the rates of death and AIDS. Yet, the underestimation of the
death rates in the high CD4 cell count strata, for example, is
likely to be lower in treated patients than in their untreated
counterparts included in the ANRS 12222 study, where loss
to follow-up rates were 1.5–5 times higher.17 An underesti-
mation of the morbidity estimates could also have arisen
because of the common difﬁculties in the diagnosis of oppor-
tunistic infections in resource-limited settings. Unfortunately,
data on non-AIDS morbidity was not available. Finally, our
pooled data concealed the heterogeneity between the studies,
especially between the African and Asian studies, but our
sample size did not allow stratifying the analysis by region.
Moreover, we hypothesized that the trend of incidence rates
FIGURE 4. Loss to follow-up incidence rates during the first
year, thereafter, and overall among HIV-infected patients
receiving ART in Africa and Asia by current CD4 cell count,
ANRS 12222 Morbidity/Mortality Collaboration.
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of mortality and morbidity across CD4 cell count strata does
not differ in large proportions according to the context. Nev-
ertheless, this pooled analysis of data from numerous stan-
dardized research studies with good monitoring and rather
low rates of patients lost to follow-up provided fairly accurate
mortality and morbidity estimates in the context of resource-
limited countries.
In conclusion, this collaborative study of 13 cohorts of
adult patients receiving ART in Africa and Asia showed that
mortality and morbidity decreased with increasing current CD4
cell count but remained substantial even with high CD4 cell
counts. Death rates seemed comparable with those observed in
Western countries, whereas AIDS rates seemed higher.
Additional efforts are necessary to allow early initiation of
ART and better diagnosis and treatment of opportunistic
infections in resource-limited settings.
ACKNOWLEDGMENTS
The ANRS 12222 Morbidity/Mortality Study Group:
Steering Committee: Xavier Anglaret, Robert Colebunders,
François Dabis, Joseph Drabo, Serge Eholié, Delphine
Gabillard, Pierre-Marie Girard, Karine Lacombe, Christian
Laurent, Vincent Le Moing, Charlotte Lewden. Other repre-
sentatives of participating studies: Gérard Allou, Clarisse
Amani-Bossé, Divine Avit, Aida Benalycherif, Pierre de Beau-
drap, Charlotte Boullé, Patrick Cofﬁe, Ali Coulibaly, Eric De-
laporte, Lise Denoeud, Serge Diagbouga, Didier Koumavi
Ekouevi, Jean-François Etard, Sabrina Eymard-Duvernay,
Patricia Fassinou, Isabelle Fournier-Nicolle, Hervé Hien,
Charlotte Huet, Issouf Konate, Sinata Koulla-Shiro, Valériane
Leroy, Olivier Marcy, Pierre Régis Martin, Nicolas Meda,
Eugène Messou, Albert Minga, Eitel Mpoudi-Ngolé, Philippe
Msellati, Boubacar Nacro, Nicolas Nagot, Ibra Ndoye,
Thérèse N’Dri-Yoman, Abdoulaye Ouédraogo, Vara Ouk,
Men Pagnaroat, Roger Salamon, Vonthanak Saphonn, Olivier
Segeral, Catherine Seyler, Besigin Tonwe-Gold, Moussa
Traore, Philippe Van de Perre, Ida Viho, Marcel Zannou.
REFERENCES
1. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on
adult mortality and early evidence of reversal after introduction of anti-
retroviral therapy in Malawi. Lancet. 2008;371:1603–1611.
2. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan
adults receiving antiretroviral treatment and survival of their HIV-uninfected
children: a prospective cohort study. Lancet. 2008;371:752–759.
3. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults access-
ing a community-based antiretroviral service in South Africa: implica-
tions for programme design. AIDS. 2005;19:2141–2148.
4. Toure S, Kouadio B, Seyler C, et al. Rapid scalingup of antiretroviral
therapy in 10,000 adults in Cote d’Ivoire: 2-year outcomes and determi-
nants. AIDS. 2008;22:873–882.
5. World Health Organization. Global HIV/AIDS Response. Epidemic
Update and Health Sector Progress Towards Universal Access. Progress
Report 2011. Geneva, Switzerland: World Health Organization/UNICEF/
UNAIDS; 2011.
6. World Health Organization. Towards universal access by 2010. How
WHO is working with countries to scale-up HIV prevention, treatment,
care and support. 2006. Available at: http://www.who.int/hiv/toronto2006/
towardsuniversalaccess.pdf. Accessed February 14, 2013.
7. The Antiretroviral Therapy in Lower Income Countries (ART-LINC)
Collaboration and ART Cohort Collaboration (ART-CC) groups. Mor-
tality of HIV-1-infected patients in the ﬁrst year of antiretroviral therapy:
comparison between low-income and high-income countries. Lancet.
2006;367:817–824.
8. Keiser O, Orrell C, Egger M, et al. Public-health and individual
approaches to antiretroviral therapy: township South Africa and Switzer-
land compared. PLoS Med. 2008,5:e148.
9. De Beaudrap P, Etard JF, Diouf A, et al. Incidence and determinants of
new AIDS-deﬁning illnesses after HAART initiation in a Senegalese
cohort. BMC Infect Dis. 2010;10:179.
10. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1
infection starting antiretroviral therapy in sub-Saharan Africa: a
collaborative analysis of scale-up programmes. Lancet. 2010;376:
449–457.
11. Brinkhof MW, Boulle A, Weigel R, et al. Mortality of HIV-infected
patients starting antiretroviral therapy in sub-Saharan Africa: comparison
with HIV-unrelated mortality. PLoS Med. 2009;6:e1000066.
12. Moh R, Danel C, Messou E, et al. Incidence and determinants of mor-
tality and morbidity following early antiretroviral therapy initiation in
HIV-infected adults in West Africa. AIDS. 2007;21:2483–2491.
13. Seyler C, Messou E, Gabillard D, et al. Morbidity before and after
HAART initiation in Sub-Saharan African HIV-infected adults: a recur-
rent event analysis. AIDS Res Hum Retroviruses. 2007;23:1338–1347.
14. Zhou J, Kumarasamy N. Predicting short-term disease progression
among HIV-infected patients in Asia and the Paciﬁc region: preliminary
results from the TREAT Asia HIV Observational Database (TAHOD).
HIV Med. 2005;6:216–223.
15. Fregonese F, Collins IJ, Jourdain G, et al. Predictors of 5-years mortality
in HIV-infected adults starting highly active antiretroviral therapy
(HAART) in Thailand. J Acquir Immune Deﬁc Syndr. 2012;60:91–98.
16. Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell
count among HIV patients initiating antiretroviral therapy: evidence from
a large cohort in Uganda. AIDS. 2011;25:851–855.
17. Lewden C, Gabillard D, Minga A, et al. CD4-speciﬁc mortality rates
among HIV-infected adults with high CD4 counts and no antiretro-
viral treatment in West Africa. J Acquir Immune Deﬁc Syndr. 2012;
59:213–219.
18. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity
and mortality across the spectrum of CD4 cell counts in HIV-infected
adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect
Dis. 2012;54:714–723.
19. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death
in adults receiving highly active antiretroviral therapy in Senegal: a 7-year
cohort study. AIDS. 2006;20:1181–1189.
20. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus
deferred antiretroviral therapy for HIV on survival. N Engl J Med.
2009;360:1815–1826.
21. Writing Committee for the CASCADE Collaboration. Timing of
HAART initiation and clinical outcomes in human immunodeﬁciency
virus type 1 seroconverters. Arch Intern Med. 2011;171:1560–1569.
22. Lewden C, Bouteloup V, De Wit S, et al. All-cause mortality in treated
HIV-infected adults with CD4 $ 500/mm3 compared with the general
population: evidence from a large European observational cohort collab-
oration. Int J Epidemiol. 2012;41:433–445.
23. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and
death rates in the EuroSIDA study: an observational study. Lancet. 2003;
362:22–29.
24. Maman D, Pujades-Rodriguez M, Nicholas S, et al. Response to antire-
troviral therapy in sub-Saharan Africa: improved survival associated with
CD4 above 500 cells/mL. AIDS. 2012;26:1393–1398.
25. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated
with CD4 cell response to antiretroviral therapy in South Africa. AIDS.
2009;23:335–342.
26. World Health Organization. Antiretroviral Therapy for HIV Infection in
Adults and Adolescents. Recommendations for a Public Health
Approach. 2010 Revision. Geneva, Switzerland: World Health Organi-
zation/UNICEF/UNAIDS; 2010.
27. Laurent C. Commentary: early antiretroviral therapy for HIV infection in
sub-Saharan Africa, a challenging new step. J Public Health Policy.
2010;31:401–406.
28. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult
HIV infection: 2010 recommendations of the International AIDS Society-
USA panel. JAMA. 2010;304:321–333.
Gabillard et al J Acquir Immune Defic Syndr  Volume 62, Number 5, April 15, 2013
560 | www.jaids.com  2012 Lippincott Williams & Wilkins
29. European AIDS Clinical Society. Guidelines for Treatment of HIV
Infected Adults in Europe, version 6.0. 2011. Available at: http://www.
europeanaidsclinicalsociety.org/. Accessed February 14, 2013.
30. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven
laboratory monitoring of HIV antiretroviral therapy in Africa (DART):
a randomised non-inferiority trial. Lancet. 2010;375:123–131.
31. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell
count, and clinical monitoring among adults with HIV receiving antiretro-
viral therapy in Uganda: randomised trial. BMJ. 2011;343:d6792.
32. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV
viral loads, CD4 cell counts, and clinical assessments versus clinical
monitoring alone for antiretroviral therapy in rural district hospitals in
Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority
trial. Lancet Infect Dis.. 2011;11:825–833.
33. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral
therapy in resource-limited settings. Ann Intern Med. 2009;151:157–166.
34. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antire-
troviral therapy in AIDS-free HIV-1-infected patients: a collaborative
analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–1363.
35. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection
with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
36. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost
to follow-up in antiretroviral treatment programmes in resource-limited
settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790.
J Acquir Immune Defic Syndr  Volume 62, Number 5, April 15, 2013 Death and AIDS on ART in Africa and Asia
 2012 Lippincott Williams & Wilkins www.jaids.com | 561
